All in all, the above results all supported that biological processes related to HEY2-based ceRNA regulatory network, tumor immunosuppressive environment, cell stemness, and IDH1 mutation may be involved in the progression and treatment of glioma. The gene discussed is HEY2; the disease is glioma.